StemRIM provided earnings guidance for the year ending July 31, 2023. For the period, The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
406 JPY | -3.10% | -12.31% | -29.76% |
05-09 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
03-13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.76% | 165M | |
+0.82% | 91.94B | |
-3.16% | 38.74B | |
+64.83% | 26.66B | |
-12.82% | 15.32B | |
-5.77% | 13.3B | |
-11.38% | 11.65B | |
+156.85% | 10.37B | |
-49.84% | 10.12B | |
+2.32% | 9.06B |
- Stock Market
- Equities
- 4599 Stock
- News StemRIM
- StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023